0000000000586573

AUTHOR

A. Turletti

showing 6 related works from this author

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast ca…

2017

Abstract Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Resul…

0301 basic medicineOncologyReceptor ErbB-2chemistry.chemical_compoundErbB-20302 clinical medicineDose-intensityExemestane80 and overNeoplasm MetastasisFulvestrantAged 80 and overeducation.field_of_studyAdvanced breast cancer Dose-intensity Everolimus Fulvestrant Hormone-receptor positiveAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2; SurgeryGeneral MedicineMiddle AgedEverolimu030220 oncology & carcinogenesisAdvanced breast cancerFemaleAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; SurgeryReceptormedicine.drugAdultmedicine.medical_specialtyPopulationSocio-culturaleBreast NeoplasmsHormone-receptor positive03 medical and health sciencesBreast cancerAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2Internal medicinemedicineHumansEverolimusAdverse effecteducationAgedNeoplasm StagingGynecologyEverolimusFulvestrantbusiness.industryfungiCancermedicine.diseaseAndrostadienesClinical trial030104 developmental biologychemistrySurgerybusinessFollow-Up StudiesThe Breast
researchProduct

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patient…

2020

<b><i>Background:</i></b> Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. <b><i>Methods:</i></b> For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). <b><i>Res…

Oncologymedicine.medical_specialtymedicine.drug_classPopulationAnastrozoleNOInternal medicineFulvestrant · First-line setting · Hormone receptor positive Advanced breast cancermedicineAdjuvant therapyProgression-free survivaleducationFulvestrantFirst-Line settingeducation.field_of_studyHormone receptor positiveAromatase inhibitorFulvestrantEVAbusiness.industrytrialsCancerEndocrine TherapyGIM-13medicine.diseaseEndocrine Therapy HR+/HER2– Advanced Breast Cancer High-Dose Fulvestrant First-Line setting EVA GIM-13 AMBRA trialsAdvanced breast cancer; First-line setting; Fulvestrant; Hormone receptor positiveOncologyHR+/HER2–Advanced Breast CancerSurgeryAMBRAbusinessHigh-DoseTamoxifenResearch Articlemedicine.drug
researchProduct

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

2019

Abstract Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-bas…

AdultOncologymedicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsVinorelbineDrug Administration ScheduleAntineoplastic AgentEfficacyCapecitabine03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalCyclophosphamideRetrospective StudiesAgedAged 80 and overAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerMetronomic ChemotherapySurvival RateMethotrexateTreatment Outcome030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAFemaleSurgerybusinessBreast NeoplasmHumanmedicine.drugThe Breast
researchProduct

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

2017

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinePharmaceutical AdjuvantsBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicinebusinessAdjuvantmedicine.drugEarly breast cancerAnnals of Oncology
researchProduct

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

2021

Abstract Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrosp…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsTriple Negative Breast NeoplasmsVinorelbineCapecitabine; Cyclophosphamide; Methotrexate; Metronomic chemotherapy; Triple-negative breast cancer; Vinorelbine; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Female; Humans; Receptor ErbB-2; Retrospective Studies; Breast Neoplasms; Triple Negative Breast NeoplasmsCapecitabineErbB-2Breast cancerTriple-negative breast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalCyclophosphamideTriple-negative breast cancerCapecitabineRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbinemedicine.diseaseClinical TrialMetronomic ChemotherapyMetastatic breast cancerRegimenMethotrexateOncologyFemalebusinessBreast NeoplasmHumanReceptormedicine.drug
researchProduct

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

2018

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July …

medicine.medical_specialtySocio-culturaleHormone-receptor positiveExemestane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerElderlyExemestaneWeight lossInternal medicineAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positive; OncologymedicineEverolimus030212 general & internal medicineStomatitisPneumonitisAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positiveEverolimusbusiness.industryCancermedicine.diseaseRashEverolimuchemistryOncology030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAAdvanced breast cancermedicine.symptombusinessResearch Papermedicine.drug
researchProduct